Cannabinoformins: Designing Biguanide-Embedded, Orally Available, Peripherally Selective Cannabinoid-1 Receptor...

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Metabolic Disorders

Background:

• Obesity and associated co-morbidities present significant health challenges.
• Targeting the cannabinoid-1 receptor (CB1R) has shown therapeutic potential but is limited by central nervous system side effects.
• Activating 5'-adenosine monophosphate kinase (AMPK) is a promising strategy for metabolic regulation.

Purpose of the Study:

• To design and synthesize novel, orally bioavailable, non-brain-penetrant CB1R antagonists.
• To incorporate a biguanide moiety to mimic AMPK activation.
• To evaluate these compounds for treating obesity-associated metabolic disorders with reduced neuropsychiatric effects.

Main Methods:

• Synthesis of a series of 3,4-diarylpyrazolines with designed peripheral restriction.
• Evaluation of CB1R binding affinity and antagonist activity.
• Assessment of AMPK activation and in vivo efficacy in diet-induced obese mice.

Main Results:

• Compounds exhibited high CB1R binding affinity and potent antagonist activity.
• Synthesized compounds demonstrated AMPK activation.
• Select compounds (36, 38-, 39-) showed <5% brain penetrance, confirming peripheral restriction.
• Compound 38- reduced food intake, body weight, improved glucose tolerance, and insulin resistance in vivo.

Conclusions:

• Novel peripherally restricted CB1R antagonists with AMPK activating properties were successfully designed and synthesized.
• These "cannabinoformin" compounds offer a promising therapeutic strategy for metabolic syndrome.
• The developed compounds demonstrate potential for treating metabolic disorders with negligible neuropsychiatric side effects.